STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] AGILENT TECHNOLOGIES, INC. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Agilent Technologies (A) insider transaction: The company’s President and CEO, also a director, exercised 12,490 stock options at $109.86 per share on 11/12/2025 and sold 12,490 common shares at $150 the same day. Following these transactions, the reporting person directly owned 33,448 shares.

The activity was conducted under a Rule 10b5-1 plan adopted on March 28, 2025. The options were granted under the 2018 Stock Plan, originally awarded on November 17, 2020, and became exercisable in four equal annual installments beginning one year after grant, with an expiration date of November 17, 2030.

Positive
  • None.
Negative
  • None.

Insights

Analyzing...

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MCDONNELL PADRAIG

(Last) (First) (Middle)
5301 STEVENS CREEK BLVD.

(Street)
SANTA CLARA CA 95051

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AGILENT TECHNOLOGIES, INC. [ A ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
11/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/12/2025 M(1) 12,490 A $109.86 45,938 D
Common Stock 11/12/2025 S(1) 12,490 D $150 33,448 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right-to-Buy)(2) $109.86 11/12/2025 M(1) 12,490 11/17/2021(3) 11/17/2030 Common Stock 12,490 $0 0 D
Explanation of Responses:
1. The options exercised and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 28, 2025.
2. Right to buy Agilent Technologies, Inc. common stock granted under the Agilent Technologies, Inc. 2018 Stock Plan, in compliance with Rule 16b-3.
3. These options were originally granted on November 17, 2020, and became exercisable in four equal annual installments beginning on the first anniversary of the date of grant.
/s/ Bret DiMarco, attorney-in-fact for Mr. McDonnell 11/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Agilent (A)’s executive report on Form 4?

An exercise of 12,490 stock options at $109.86 and a same‑day sale of 12,490 shares at $150 on 11/12/2025.

How many Agilent shares does the reporting person own after the transactions?

Direct beneficial ownership is 33,448 shares after the reported transactions.

Was the trade under a Rule 10b5-1 plan?

Yes. The transactions were effected pursuant to a Rule 10b5-1 plan adopted on March 28, 2025.

What were the option terms related to the exercise?

The employee stock option had a $109.86 exercise price, was granted on Nov 17, 2020, vested in four annual installments starting one year later, and expires on Nov 17, 2030.

What is the reporting person’s role at Agilent (A)?

The reporting person is a Director and an Officer, serving as President and CEO.

Were any derivative securities remaining after the exercise?

No. The filing shows 0 derivative securities beneficially owned following the exercise.
Agilent Technologies Inc

NYSE:A

A Rankings

A Latest News

A Latest SEC Filings

A Stock Data

41.64B
282.61M
0.29%
92.62%
1.07%
Diagnostics & Research
Laboratory Analytical Instruments
Link
United States
SANTA CLARA